000280238 001__ 280238
000280238 005__ 20250827101637.0
000280238 0247_ $$2doi$$a10.1038/s41598-025-13367-8
000280238 0247_ $$2pmid$$apmid:40754554
000280238 0247_ $$2pmc$$apmc:PMC12319074
000280238 037__ $$aDZNE-2025-00916
000280238 041__ $$aEnglish
000280238 082__ $$a600
000280238 1001_ $$aKonen, Franz Felix$$b0
000280238 245__ $$aPilot study of cerebrospinal fluid biomarkers reveals inflammatory changes in patients with paranoid schizophrenia.
000280238 260__ $$a[London]$$bSpringer Nature$$c2025
000280238 3367_ $$2DRIVER$$aarticle
000280238 3367_ $$2DataCite$$aOutput Types/Journal article
000280238 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756201202_31524
000280238 3367_ $$2BibTeX$$aARTICLE
000280238 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280238 3367_ $$00$$2EndNote$$aJournal Article
000280238 520__ $$aParanoid schizophrenia is a severe mental illness with both positive and negative symptoms. Currently, the role of peripheral and central inflammation is increasingly suspected as possible factor in the pathogenesis of schizophrenia. This retrospective, monocentric pilot study investigated 35 patients (15/35 female) diagnosed with paranoid schizophrenia after exclusion of possible underlying neuroinflammatory disorders to assess for inflammatory changes of the cerebrospinal fluid (CSF) and associated signs of neurodegeneration. Kappa free light chains (KFLC), a panel of 21 cyto- and chemokines, and neurofilament light chains (NFL) as surrogate parameters for neuro-inflammation and -degeneration were determined in patients with paranoid schizophrenia as well as age- and sex-matched inflammatory (n = 35) and non-inflammatory controls (n = 40). Patients with paranoid schizophrenia exhibited significantly higher intrathecal synthesized fractions of KFLC than non-inflammatory controls. KFLC-positive patients with paranoid schizophrenia had significantly higher NFL concentrations in CSF than KFLC-negative patients according to Reiber´s diagram. NFL concentrations in CSF of patients with paranoid schizophrenia were associated with illness duration, frequency of psychotic episodes, and amount of antipsychotic treatment attempts. This pilot study highlights inflammatory changes in the CSF among a specific subgroup of patients with paranoid schizophrenia, positively correlating with elevated NFL levels in CSF.
000280238 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280238 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280238 650_7 $$2Other$$aCerebrospinal fluid
000280238 650_7 $$2Other$$aChemokines
000280238 650_7 $$2Other$$aCytokines
000280238 650_7 $$2Other$$aKappa free light chains
000280238 650_7 $$2Other$$aNeurofilament light chains
000280238 650_7 $$2Other$$aParanoid schizophrenia
000280238 650_7 $$2NLM Chemicals$$aBiomarkers
000280238 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000280238 650_7 $$2NLM Chemicals$$aneurofilament protein L
000280238 650_2 $$2MeSH$$aHumans
000280238 650_2 $$2MeSH$$aSchizophrenia, Paranoid: cerebrospinal fluid
000280238 650_2 $$2MeSH$$aFemale
000280238 650_2 $$2MeSH$$aMale
000280238 650_2 $$2MeSH$$aPilot Projects
000280238 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000280238 650_2 $$2MeSH$$aAdult
000280238 650_2 $$2MeSH$$aMiddle Aged
000280238 650_2 $$2MeSH$$aRetrospective Studies
000280238 650_2 $$2MeSH$$aInflammation: cerebrospinal fluid
000280238 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000280238 7001_ $$aGehring, Philipp Sebastian$$b1
000280238 7001_ $$aMaier, Hannah Benedictine$$b2
000280238 7001_ $$aSchröder, Sebastian$$b3
000280238 7001_ $$aTürker, Seda Nur$$b4
000280238 7001_ $$aFrieling, Helge$$b5
000280238 7001_ $$aBleich, Stefan$$b6
000280238 7001_ $$aHuss, André$$b7
000280238 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b8$$udzne
000280238 7001_ $$aLüdecke, Daniel$$b9
000280238 7001_ $$aGallinat, Jürgen$$b10
000280238 7001_ $$aMalchow, Berend$$b11
000280238 7001_ $$aHansen, Niels$$b12
000280238 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b13$$udzne
000280238 7001_ $$aNeyazi, Alexandra$$b14
000280238 7001_ $$aSkripuletz, Thomas$$b15
000280238 7001_ $$aCAP$$b16$$eCollaboration Author
000280238 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-025-13367-8$$gVol. 15, no. 1, p. 28319$$n1$$p28319$$tScientific reports$$v15$$x2045-2322$$y2025
000280238 8564_ $$uhttps://pub.dzne.de/record/280238/files/DZNE-2025-00916.pdf$$yOpenAccess
000280238 8564_ $$uhttps://pub.dzne.de/record/280238/files/DZNE-2025-00916.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280238 909CO $$ooai:pub.dzne.de:280238$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000280238 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b8$$kExtern
000280238 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000280238 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280238 9141_ $$y2025
000280238 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-07-29T15:28:26Z
000280238 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-07-29T15:28:26Z
000280238 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280238 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2024-12-18
000280238 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000280238 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280238 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000280238 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000280238 980__ $$ajournal
000280238 980__ $$aVDB
000280238 980__ $$aUNRESTRICTED
000280238 980__ $$aI:(DE-2719)1410006
000280238 9801_ $$aFullTexts